CA
NZ
UK
AU
IND
US
…
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -29.02M | -15.89M | -17.36M | -13.43M | -11.88M |
| Net income | -27.41M | -8.86M | -15.00M | -13.21M | -11.88M |
| Selling general administrative | 11.67M | 8.39M | 6.79M | 6.31M | 5.30M |
| Gross profit | - | -0.16M | - | - | 0.00M |
| Reconciled depreciation | 0.13M | 0.16M | 0.20M | 0.20M | 0.07M |
| Ebit | -30.64M | -22.97M | -19.74M | -17.52M | -18.28M |
| Ebitda | -31.98M | -29.53M | -21.89M | -21.39M | -18.21M |
| Depreciation and amortization | -1.33M | -6.56M | -2.15M | -3.86M | 0.07M |
| Non operating income net other | - | - | 2.37M | 4.08M | 3.15M |
| Operating income | -30.64M | -22.97M | -19.74M | -17.52M | -15.03M |
| Other operating expenses | 30.64M | 22.97M | 19.74M | 17.52M | 15.03M |
| Interest expense | -1.61M | 7.07M | 0.01M | 8.15M | 0.00M |
| Tax provision | - | - | 0.00M | -0.23M | - |
| Interest income | 0.24M | 0.31M | - | 4.08M | 3.19M |
| Net interest income | 0.24M | 0.31M | 0.01M | 0.01M | 0.00M |
| Income tax expense | -1.61M | -7.03M | -2.36M | -0.23M | 3.15M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 30.64M | 22.97M | 19.74M | 17.52M | 15.03M |
| Cost of revenue | - | 0.16M | - | - | 0.00M |
| Total other income expense net | 1.61M | 7.07M | 2.39M | 4.09M | 3.15M |
| Net income from continuing ops | -29.02M | -15.89M | -17.36M | -13.21M | -11.88M |
| Net income applicable to common shares | - | -15.89M | -17.36M | -13.21M | -11.88M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 38.22M | 57.42M | 84.09M | 29.03M | 25.23M |
| Intangible assets | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M |
| Other current assets | 2.62M | 2.45M | 1.59M | 0.16M | 0.53M |
| Total liab | 12.14M | 5.23M | 5.10M | 11.27M | 9.66M |
| Total stockholder equity | 26.07M | 52.19M | 78.99M | 17.76M | 15.57M |
| Deferred long term liab | - | - | - | - | 5.82M |
| Other current liab | 4.22M | -0.12M | 2.16M | 1.67M | 0.16M |
| Common stock | 0.03M | 0.03M | 0.03M | 0.07M | 0.05M |
| Capital stock | 0.03M | 0.03M | 0.03M | 0.07M | 0.05M |
| Retained earnings | -131.60M | -101.83M | -72.81M | -56.92M | -39.56M |
| Other liab | - | - | 1.41M | 8.19M | 5.82M |
| Other assets | 0.00M | - | - | 0.69M | - |
| Cash | 23.55M | 43.15M | 70.90M | 15.17M | 10.73M |
| Total current liabilities | 6.82M | 4.82M | 3.62M | 2.92M | 3.57M |
| Current deferred revenue | - | - | - | - | 1.15M |
| Net debt | -22.98M | -42.69M | -70.74M | -14.90M | -10.36M |
| Short term debt | 0.10M | 0.12M | 0.10M | 0.12M | 0.10M |
| Short long term debt total | 0.57M | 0.45M | 0.16M | 0.28M | 0.38M |
| Other stockholder equity | 157.65M | 153.99M | 151.73M | 74.54M | 55.05M |
| Property plant equipment | - | - | 0.45M | 0.69M | 0.60M |
| Total current assets | 26.27M | 45.60M | 72.50M | 17.20M | 13.48M |
| Net tangible assets | - | - | 67.84M | 6.61M | 4.42M |
| Net receivables | 0.10M | 0.02M | 0.04M | 0.00M | 0.01M |
| Inventory | - | -0.02M | -0.04M | 1.86M | 2.21M |
| Accounts payable | 2.50M | 4.82M | 1.36M | 1.13M | 2.15M |
| Accumulated other comprehensive income | -0.01M | 0.01M | 0.04M | 0.07M | 0.03M |
| Common stock total equity | - | - | - | 0.07M | 0.05M |
| Retained earnings total equity | - | - | - | -56.92M | -39.56M |
| Non currrent assets other | -0.00M | 0.28M | 0.34M | - | 11.15M |
| Non current assets total | 11.94M | 11.83M | 11.59M | 11.83M | 11.75M |
| Capital lease obligations | 0.57M | 0.45M | 0.16M | 0.28M | 0.38M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.07M | -0.02M | -0.37M | -0.05M | -0.42M |
| Change to liabilities | - | 0.23M | -1.02M | -0.23M | 1.86M |
| Total cashflows from investing activities | - | -0.02M | -0.37M | -0.05M | -0.42M |
| Total cash from financing activities | -0.02M | 74.72M | 22.55M | 20.85M | 12.04M |
| Change to operating activities | - | 0.80M | 0.98M | -3.05M | 1.17M |
| Net income | -29.02M | -15.89M | -17.36M | -13.21M | -11.88M |
| Change in cash | -27.76M | 55.73M | 4.44M | 3.60M | -0.58M |
| Begin period cash flow | 70.90M | 15.17M | 10.73M | 7.13M | 7.71M |
| End period cash flow | 43.15M | 70.90M | 15.17M | 10.73M | 7.13M |
| Total cash from operating activities | -27.64M | -18.95M | -17.77M | -17.20M | -12.20M |
| Issuance of capital stock | 0.00M | 74.68M | 22.56M | 19.29M | 12.03M |
| Depreciation | 0.13M | 0.16M | 0.20M | 0.20M | 0.07M |
| Other cashflows from investing activities | - | - | 0.00M | 0.00M | - |
| Change to account receivables | - | - | 0.13M | - | - |
| Sale purchase of stock | - | - | 22.57M | 20.85M | 12.04M |
| Other cashflows from financing activities | -0.02M | 0.04M | -0.01M | 1.56M | 0.02M |
| Change to netincome | - | -4.26M | -0.57M | -2.53M | -2.00M |
| Capital expenditures | 0.07M | 0.02M | 0.38M | 0.05M | 0.42M |
| Cash flows other operating | - | - | 0.81M | -1.43M | -0.25M |
| Exchange rate changes | - | - | - | - | -0.01M |
| Cash and cash equivalents changes | - | - | 4.40M | 3.60M | -0.58M |
| Change in working capital | 0.22M | 1.04M | -0.04M | -2.14M | 1.61M |
| Stock based compensation | 2.27M | 2.37M | 1.68M | 1.54M | 1.14M |
| Other non cash items | -1.24M | 0.10M | 0.09M | 0.48M | -3.15M |
| Free cash flow | -27.71M | -18.97M | -18.15M | -17.25M | -12.62M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| MBRX Moleculin Biotech Inc |
-0.02 0.24% |
8.30 | - | - | - | 0.40 | 0.43 |
| NVO Novo Nordisk A/S |
-0.04 0.09% |
40.41 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-12.16 2.20% |
540.99 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
9.56 0.99% |
970.83 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
| Name | Title | Year Born |
|---|---|---|
| Mr. Walter V. Klemp | Founder, Chairman, Pres & CEO | 1960 |
| Mr. Jonathan P. Foster CPA | Exec. VP & CFO | 1964 |
| Dr. Donald H. Picker Ph.D. | Chief Scientific Officer | 1946 |
| Dr. Waldemar Priebe Ph.D. | Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board | NA |
| Dr. Robert C. Shepard FACP, M.D., F.A.C.P. | Chief Medical Officer of Annamycin | 1952 |
| Dr. John Paul Waymack M.D., Sc.D. | Sr. Chief Medical Officer | 1952 |
| Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer of New Products | 1955 |
| Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D. | European Chief Medical Officer | NA |
| Ms. Jacqueline Northcut | Consultant | 1962 |
| Mr. Louis Ploth Jr. | Independent Advisor | 1954 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.02%
Communication Services
+0.15%
Consumer Cyclical
+0.00%
Consumer Defensive
-0.22%
Energy
-0.13%
Financial Services
+0.03%
Financials
+0.71%
Healthcare
+0.93%
Industrials
+0.48%
Real Estate
-0.03%
Technology
+0.76%
Utilities
-0.12%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...